Personalized ASO therapy represents the next frontier in precision medicine for neurodegenerative diseases, particularly for rare genetic variants like corticobasal degeneration (CBS) and progressive supranuclear palsy (PSP). Following the landmark success of the Ionis Pharmaceuticals model—exemplified by FDA-approved therapies like [Nusinersen (Spinraza)](https://clinicaltrials.gov/study/NCT03227016) for spinal muscular atrophy and [Tofersen](https://clinicaltrials.gov/study/NCT02623699) for SOD1 ALS—personalized ASO approaches are now being developed for individually rare but collectively significant neurodegenerative conditions.
[@bennett2024][@rinaldi2022]
Rationale
The Challenge of Rare Neurodegenerative Diseases
Individually rare, collectively significant: While CBS, PSP, and other atypical parkinsonisms affect relatively small patient populations individually, together they represent thousands of patients with no disease-modifying treatments
Genetic underpinnings: Many cases have identified genetic risk factors (e.g., [MAPT](/genes/mapt) mutations in PSP, [GRN](/genes/grn) mutations in CBS/FTD) that could be targeted with ASOs
Clear molecular targets: Unlike sporadic cases with complex polygenic risk, genetic variants often have well-defined loss-of-function mechanisms amenable to ASO intervention
Why ASOs Are Ideal for Personalization
...
Overview
Personalized ASO therapy represents the next frontier in precision medicine for neurodegenerative diseases, particularly for rare genetic variants like corticobasal degeneration (CBS) and progressive supranuclear palsy (PSP). Following the landmark success of the Ionis Pharmaceuticals model—exemplified by FDA-approved therapies like [Nusinersen (Spinraza)](https://clinicaltrials.gov/study/NCT03227016) for spinal muscular atrophy and [Tofersen](https://clinicaltrials.gov/study/NCT02623699) for SOD1 ALS—personalized ASO approaches are now being developed for individually rare but collectively significant neurodegenerative conditions.
[@bennett2024][@rinaldi2022]
Rationale
The Challenge of Rare Neurodegenerative Diseases
Individually rare, collectively significant: While CBS, PSP, and other atypical parkinsonisms affect relatively small patient populations individually, together they represent thousands of patients with no disease-modifying treatments
Genetic underpinnings: Many cases have identified genetic risk factors (e.g., [MAPT](/genes/mapt) mutations in PSP, [GRN](/genes/grn) mutations in CBS/FTD) that could be targeted with ASOs
Clear molecular targets: Unlike sporadic cases with complex polygenic risk, genetic variants often have well-defined loss-of-function mechanisms amenable to ASO intervention
Why ASOs Are Ideal for Personalization
| Factor | Explanation | |--------|-------------| | Sequence specificity | ASOs can be designed to target any unique mutation with single-nucleotide precision | | Rapid development | From gene identification to IND can take 12-18 months vs. 5+ years for small molecules | | Allele-selective targeting | Can selectively silence mutant alleles while preserving wild-type function | | Modifiable chemistry | ASO backbone and modifications can optimize tissue delivery and half-life | | Regulatory precedent | FDA has approved 15+ ASOs, establishing clear regulatory pathways |
Mechanism of Action
Standard ASO Mechanisms
Mermaid diagram (expand to render)
For CBS/PSP: Specific Mechanisms
MAPT Mutations (PSP)
Many pathogenic [MAPT](/genes/mapt) mutations cause exon 10 inclusion/skipping, altering the 3R-tau/4R-tau ratio
ASOs can be designed to normalize tau isoform ratios by modulating splice site usage
Reduces production of mutant tau protein that forms neurofibrillary tangles
[ALS Association - ASO Research](https://www.als.org)
References
[Bennett CF, et al, Therapeutic applications of antisense oligonucleotides in central nervous system disorders (2024)](https://doi.org/10.1016/j.neuron.2024.01.010)
[Rinaldi C, et al, Antisense oligonucleotide therapy for rare genetic diseases (2022)](https://doi.org/10.1172/jci.insight.152763)
[Corey DR, RNA therapeutics in neurology: progress and future directions (2020)](https://pubmed.ncbi.nlm.nih.gov/32852077/)
[Miller T, et al, Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS (2022)](https://doi.org/10.1056/NEJMoa2104705)
[Finkel RS, et al, Nusinersen in Infantile-Onset Spinal Muscular Atrophy (2017)](https://doi.org/10.1056/NEJMoa1702752)
[Kordas G, et al, Antisense oligonucleotide delivery to the CNS (2022)](https://doi.org/10.1016/j.ymthe.2022.04.015)
[Houde C, et al, Individualized antisense oligonucleotide therapy for a rare neurological disease (2023)](https://doi.org/10.1101/2023.01.15.524199)
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
[4R-tau strain-specific spreading patterns in PSP vs CBD](/analysis/SDA-2026-04-01-gap-005) 🔄
Pathway Diagram
The following diagram shows the key molecular relationships involving Personalized Antisense Oligonucleotide (ASO) Therapy discovered through SciDEX knowledge graph analysis: